Patents Assigned to Hutchison Medipharma Limited
  • HETEROAROMATIC COMPOUNDS AND USES THEREOF
    Publication number: 20240092774
    Abstract: Providing heteraromatic compounds and uses thereof. In particular, providing heteraromatic compounds of formula (I), pharmaceutical compositions comprising same, methods for preparing same and uses thereof, wherein the variables are as defined in the description.
    Type: Application
    Filed: September 17, 2021
    Publication date: March 21, 2024
    Applicant: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Wei-Guo SU, Weihan ZHANG, Haibin YANG
  • Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
    Patent number: 11896592
    Abstract: Provided are certain triazolopyridines and triazolopyrazines of Formula 1, wherein X, Y, R1, R2, R3, R4 and R5 have any of the meanings described herein; processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: February 13, 2024
    Assignee: Hutchison Medipharma Limited
    Inventors: Wei-Guo Su, Hong Jia, Guangxiu Dai
  • Substituted piperazines as BTK inhibitors
    Patent number: 11655254
    Abstract: Provided are heteroaryl heterocyclic compounds of formula (I), pharmaceutical compositions comprising same, methods for preparing same, and uses thereof, wherein the variables are as defined in the description. The compounds are Btk inhibitors.
    Type: Grant
    Filed: April 25, 2022
    Date of Patent: May 23, 2023
    Assignee: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Guangxiu Dai, Kun Xiao
  • Crystalline forms of (S)-4-amino-6-((1-(3-chloro-6-phenylimidazo[1,2-b]pyridazine-7-yl)ethyl)amino)pyrimidine-5-carbonitrile as inhibitors of phosphatidylinositol-3-kinase
    Patent number: 11584750
    Abstract: The present invention belongs to the pharmaceutical field, and provides crystalline forms, solvates and the crystalline forms thereof of the compound (S)-4-amino-6-((1-(3-chloro-6-phenylimidazo[1,2-b]pyridazin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile of the formula shown below, and the pharmaceutical compositions comprising the same as well as the methods of preparing the same and the use thereof.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: February 21, 2023
    Assignee: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Zhenping Wu, Wenji Li, Ling Feng
  • CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE
    Publication number: 20220372005
    Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof, and/or solvates racemic mixtures, enantiomers, diasteromers, and tautomers thereof, wherein A, R1, R2, R3, R3?, R4, R4?, R5, R6, R7, R8, m, and n are as defined in the detailed description.
    Type: Application
    Filed: May 18, 2022
    Publication date: November 24, 2022
    Applicant: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Wei-Guo SU, Guangxiu DAI, Kun XIAO
  • 2-(3?-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4?-bipyridin]-2?-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one as a BTK inhibitor
    Patent number: 11478474
    Abstract: The present invention relates to heteroaryl heterocyclic compounds, e.g., the compound of the formula shown below, pharmaceutical compositions comprising same, methods for preparing same, and uses thereof.
    Type: Grant
    Filed: October 20, 2021
    Date of Patent: October 25, 2022
    Assignee: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Guangxiu Dai, Kun Xiao
  • Cycloolefin substituted heteroaromatic compounds and their use
    Patent number: 11414390
    Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof, and/or solvates, racemic mixtures, enantiomers, diasteromers, and tautomers thereof, wherein A, R1, R2, R3, R3?, R4, R4?, R5, R6, R7, R8, m, and n are as defined in the detailed description.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: August 16, 2022
    Assignee: Hutchison Medipharma Limited
    Inventors: Wei-Guo Su, Guangxiu Dai, Kun Xiao
  • Salts of a compound and the crystalline forms thereof
    Patent number: 11396507
    Abstract: The present invention belongs to the pharmaceutical field, and provides the pharmaceutically acceptable salts of the compound (S)-7-(4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido[3,4-b]pyrazin-5-amine and the crystalline forms thereof, the solvates and the crystalline forms thereof, the pharmaceutical compositions comprising the same as well as the methods of preparing the same and the use thereof.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: July 26, 2022
    Assignee: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Zhenping Wu, Wenji Li, Ling Feng
  • PHARMACEUTICAL PREPARATION OF FRUQUINTINIB AND USE THEREOF
    Publication number: 20220125789
    Abstract: A pharmaceutical composition of fruquintinib comprising filler and its preparing process are disclosed. The filler is selected from starch, microcrystalline cellulose or a combination thereof. The composition is in the form of a tablet or capsule and can be used in the treatment of cancer, such as colorectal cancer, non-small cell lung cancer, and gastric cancer.
    Type: Application
    Filed: November 15, 2019
    Publication date: April 28, 2022
    Applicant: Hutchison Medipharma Limited
    Inventors: Zhongzhou Liu, Jinli Wu, Chongdong Fu
  • CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE
    Publication number: 20210363115
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, and/or solvates, racemic mixtures, enantiomers, diasteromers, and tautomers thereof, wherein A, R1, R2, R3, R3?, R4, R4?, R5, R6, R7, R8, m, and n are as defined in the detailed description of the invention.
    Type: Application
    Filed: September 7, 2018
    Publication date: November 25, 2021
    Applicant: Hutchison Medipharma Limited
    Inventors: Wei-Guo Su, Guangxiu Dai, Kun Xiao
  • Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide
    Patent number: 11046674
    Abstract: Crystalline forms of compound 6-(6,7-dimethoxyquinazolin-4-yloxy)-N,2-dimethylbenzofuran-3-carboxamide, pharmaceutical compositions and the methods of preparation and the use thereof.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: June 29, 2021
    Assignee: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Zhenping Wu, Wenji Li, Yuping Chu
  • CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR
    Publication number: 20210154192
    Abstract: Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.
    Type: Application
    Filed: February 3, 2021
    Publication date: May 27, 2021
    Applicant: Hutchison Medipharma Limited
    Inventors: Wei-Guo Su, Hong Jia, Guangxiu Dai
  • Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
    Patent number: 10946014
    Abstract: Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: March 16, 2021
    Assignee: Hutchison Medipharma Limited
    Inventors: Wei-Guo Su, Hong Jia, Guangxiu Dai
  • CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR
    Publication number: 20200179377
    Abstract: Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.
    Type: Application
    Filed: November 8, 2019
    Publication date: June 11, 2020
    Applicant: Hutchison Medipharma Limited
    Inventors: Guangxiu Dai, Hong Jia, Wei-Guo Su
  • Imidazopyridazine compounds and their use
    Patent number: 10611777
    Abstract: This disclosure provides novel imidazopyridazine compounds of formula (I) and pharmaceutical acceptable salt thereof, pharmaceutical compositions containing them, a process for preparing them, and their practical effect in inhibiting PI3K and potential use in treating a disease responsive to inhibition of PI3K, for example, an inflammatory disease, autoimmune disease or cancer.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: April 7, 2020
    Assignee: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Wei-Guo Su, Guangxiu Dai, Weihan Zhang, Wei Deng
  • Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide
    Patent number: 10519142
    Abstract: The present invention relates to the pharmaceutical field, provides novel crystalline forms, solvates and the crystalline forms thereof of compound 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide, pharmaceutical compositions, as well as the methods of preparation and the use thereof.
    Type: Grant
    Filed: September 7, 2015
    Date of Patent: December 31, 2019
    Assignee: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Zhenping Wu, Wenji Li, Yuping Chu
  • Pyrrolopyrimidine compounds and uses thereof
    Patent number: 10369153
    Abstract: The present disclosure provides pyrrolopyrimidine compounds and methods of use therefor. For example, the disclosure provides certain pyrrolopyrimidine compounds capable of inhibiting JAK kinases. The disclosure further provides the pharmaceutical compositions containing these pyrrolopyrimidine compounds, and use of these pyrrolopyrimidine compounds in the treatment of disorders or diseases, such as inflammatory diseases and cancer.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: August 6, 2019
    Assignee: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Wei-Guo Su, Wei Deng, Jinshui Li, Jianguo Ji
  • Imidazopyridazine compounds and their use
    Patent number: 10208066
    Abstract: This disclosure provides novel imidazopyridazine compounds of formula (I) and pharmaceutical acceptable salt thereof, pharmaceutical compositions containing them, a process for preparing them, and their practical effect in inhibiting PI3K and potential use in treating a disease responsive to inhibition of PI3K, for example, an inflammatory disease, autoimmune disease or cancer.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: February 19, 2019
    Assignee: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Wei-Guo Su, Guangxiu Dai, Welhan Zhang, Wei Deng
  • CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR
    Publication number: 20180263977
    Abstract: Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.
    Type: Application
    Filed: April 4, 2018
    Publication date: September 20, 2018
    Applicant: Hutchison Medipharma Limited
    Inventors: Wei-Guo Su, Hong Jia, Guangxiu Dai
  • Substituted pyrido[3,4-b]pyrazines as Syk inhibitors
    Patent number: 10052330
    Abstract: Provided are pyridopyrazine compounds of formula (I), pharmaceutical compositions thereof and methods of use therefore, wherein R1, R2, R3, R4 and m are as defined in the specification.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: August 21, 2018
    Assignee: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Wei-Guo Su, Wei Deng, Jianguo Ji